Melbourne, Australia, 03 May 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce they will be presenting at the Association for Research in Vision and Ophthalmology (ARVO).
OccuRx will present new research titled ‘Oral delivery of the anti-fibrotic, FT011, achieves safe and robust intraocular levels of exposure in subjects undergoing glaucoma filtration surgery (GFS) during the virtual conference held between 3rd – 7th May 2020.
The presentation of this new research will demonstrate the pre-clinical trial results for their novel oral anti-fibrotic small molecule compound, FT011. The findings demonstrate that oral administration of FT011 to patients undergoing GFS results in safe and robust exposure levels of the drug in the aqueous humor (AH) and Tenon’s capsule (TC). The investigational compound was safe and well tolerated after four weeks of dosing.
Professor Darren Kelly, Executive Chair of OccuRx said, “Despite modern modifications in surgical technique, significant limitations still exist in wound healing management following GFS. We are pleased to present these promising results from our -clinical trial that demonstrate oral delivery of FT011 leads to safe and adequate exposure levels in ocular tissues. Ultimately this may improve the wound healing process following GFS and improve surgical safety and efficacy.
The full paper reference for this research can be found below.
Paper publication reference:
JF Gaskin, N Kerr, MP Papadimitriou, RCK Kong, FL Khong, D Kelly. “Oral delivery of the anti-fibrotic, FT011, achieves safe and robust intraocular levels of exposure in subjects undergoing glaucoma filtration surgery” Investigative Ophthalmology & Visual Science June 2020, Vol.61, (7):1419